The Provis Team
Directors and Officers of Provis Infusion Clinic Inc.
Provis Infusion Clinic Inc. was established by a group of health care professionals who are interested in the changing landscape of healthcare delivery in Canada. Our four directors have many years of experience in designing, founding and operating health care companies and freestanding clinics in Canada.
The Provis Team
Graham Vincent, BPHE, MBA
President, Provis Infusion Clinic.
Graham has over 25 years of business management experience in providing patient oriented services in the healthcare industry. He has successfully built and lead several leading healthcare organizations. Graham provides overall managment and oversees administration of the clinic.
Physician Team
Our physician team provides on-site direct supervision of all infusions. Our team consists of emergency room physicians and oncologists.
Pharmaceutical Team
Our pharmaceutical team consists of three experienced Oncology Pharmacists and three Pharmacy Technicians. Your medications are always mixed on site by a Pharmacy Technician who are supervised by the Pharmacist. All of the medication compounding is done on site to make things as seamless and flexible for the patient as possible. Ostap Mojsiak our Director of Pharmaceutical Services oversees our team.
Administrative Staff
Our helpful and friendly office staff provide efficient and seamless administrative services from first patient contact to completion of treatment. They take pride in anticipating the needs of our patients and referring physicians while ensuring smooth business operations at the clinic.
Nursing Team
We recognize the invaluable contribution an experienced nurse can make to the patient experience in intravenous therapies. Our nurses are highly trained and certified in their oncology specialty, with many years of experience in patient care. All of our nursing staff also work at major cancer centres in Toronto. Their compassion and respect for each patient’s individuality has a lasting, positive effect on the well being of our patients.
Why Choose Provis?
- Infusion Services Since 2005
- Over 13,000+ Infusions To Date
- Most Comprehensive Oncology Drug Formulary in Canada
- Onsite Medication Compounding Facility
- Experienced Pharmacists On-Site
- Experienced Oncology Trained Nurses
- Supervising Physician On-Site
15 Year Anniversary!
The Provis Infusion Clinic is please to announce that August 2020 marks the 15 anniversary of the Provis Infusion Clinic. We are looking forward to the next 15 years of providing high quality infusion services.COVID 19 Trial
Provis is pleased to partner with University Health Network, University of Toronto, EMS services and Police Services on a Phase 3 Clinical Trial focusing on COVUD 19. Called 'Cobra' the trial will look at the effectiveness of the vaccine BCG in the minimization of the COVID symptoms and the contraction of the virus.New Medications
Venofer™ (Iron Sucrose) Onivyde™ (Irinotecan liposome for injection) Tecentriq™ (Atezolizumab) Renflexis™ (Infliximab) Yondelis™ (Trabectedin) Yervoy™ (Ipilimumab)Kyprolis™ (Carfilzomib) receives Health Canada approval.
Health Canada has approved Kyprolis™ (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy.Opdivo™ (Nivolumab) receives Health Canada approval.
Opdivo™ is the first anti PD-1 (programmed death-1) approved to treat previously untreated cases of BRAF V600 wild-type unresectable or metastatic melanoma in adults. The approval was made under the Health Canada Priority Review process, after having met the criteria of substantial evidence of clinical effectiveness providing an improved benefit/risk profile over existing therapies. Provis is also able to provide Opdivo™ for other indications if required.Keytruda™ (Pembrolizumab) now offered at Provis
AUTHORIZATION WITH CONDITIONS OF KEYTRUDA™ for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitorUpdate – Patient Support Programs
Keytruda®, Perjeta®, Herceptin®, Avastin®,Jevtana®, Rituxan®, Abraxane® Kadcyla® Tecentriq® Yervoy® Opdivo® Patients: Provis participates in the Roche Patient Assistance Program, the , the OnCare Program, the Merck Care Oncology, and Celgene Abraxane® Access Program . These program offers financial assistance to qualified patients receiving Tecentriq®, Keytruda®, Perjeta®, Herceptin®, Avastin®, Rituxan®, Abraxane®,Opdivo® ® and Kadcyla® Read More >>
Non-Muscle Invasive Bladder Cancer
Provis works with the University Urology Associates (UUA), in providing the compounded MMC for electronically stimulated Mitomycin-C (EMDA MMC) to treat non-muscle invasive bladder cancer.